.png){kind=icon}
.png){kind=icon}
Return
Plazomicin activity against carbapenem-resistant Escherichia coli: A brief report
.png){kind=icon}
PRE
AI
K
S
S
P
R
J
C
DOI：10.1016/j.ijmmb.2026.101078.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Carbapenem-resistant Escherichia coli (CR-E. coli) pose major therapeutic challenges. We evaluated the activity of plazomicin against 52 CR-E.coli isolates from a Mumbai tertiary hospital. Plazomicin demonstrated potent activity (Minimum Inhibitory Concentration [MIC] 0.19-2 mg/L) against isolates, including those harboring NDM or OXA-48-like carbapenemases, with or without aminoglycoside-modifying enzymes (AMEs). In contrast, isolates carrying 16S rRNA methyltransferases (RMTs) (e.g., rmtB1, rmtC, rmtF1) exhibited high-level resistance (MICs of >= 256 mu g/mL). These findings not only highlight the advantage of plazomicin in AME-positive, RMTnegative strains, but also warn about the threat of emerging 16S RMT-mediated resistance that limit its clinical utility.
Keywords:
Antimicrobial resistance
Plazomicin
Genes
Journal
IF:
1.3
Papers:
91
Citations:
2.0K